KT-5000

KT-5000 is a preclinical small molecule drug candidate developed by Rakovina Therapeutics. It is part of the "KT-5000 series," which comprises highly selective ATR (ataxia telangiectasia and Rad3-related protein) inhibitors targeting the DNA damage response pathway. ATR inhibition is a promising strategy to exploit tumor vulnerabilities in various cancers, particularly solid tumors with high unmet medical need. The compounds are engineered for optimal selectivity and tolerability, making them suitable for combination use with other DNA damage response-targeted agents or standard-of-care therapies. The program aims to address a wide range of solid tumors and represents an opportunity for strategic partnerships in oncology[1][4].

Other names

KT-5000 seriesKT5000 seriesKT 5000 seriesKT-5000AI seriesKT5000AI seriesKT 5000AI series